Merck

EMD Serono appoints makes key oncology appointments

Thursday, May 28, 2015 02:54 PM

EMD Serono, the U.S. biopharmaceutical business of Germany’s Merck, has announced two critical management appointments to lead its entry into oncology. EMD Serono's diversified oncology and immuno-oncology pipeline includes multiple, high-priority projects currently in development to optimize patient outcomes in challenging cancers that have significant unmet patient need.

More... »

Quest Diagnostics

Fosun Pharma, HOPU Investments, CEL Healthcare Fund, WuXi PharmaTech to acquire Ambrx

Friday, May 22, 2015 01:50 PM

A consortium—consisting of entities affiliated with Shanghai Fosun Pharmaceutical Group, HOPU InvestmentsChina Everbright’s Healthcare Fund and WuXi PharmaTech—has signed a merger agreement to acquire Ambrx. The transaction is expected to close in the second quarter of 2015, subject to receipt of certain regulatory approvals and satisfaction of customary closing conditions.

More... »


Moderna launches venture company Elpidera for rare diseases

Wednesday, May 13, 2015 11:57 AM

Moderna Therapeutics, a Cambridge, Mass.-based developer of messenger RNA (mRNA) Therapeutics, has launched Elpidera, a new Moderna venture focused exclusively on the advancement of mRNA-based medicines for the treatment of rare diseases.

More... »

Report: Pipeline advancements, asset acquisitions fueled biotech R&D spend in 2014

Wednesday, April 29, 2015 12:17 PM

The combined spend on R&D for the peer group of 35 mid-cap biotech companies increased by nearly $2 billion to reach a total of $9.7 billion in 2014, primarily thanks to top spenders Regeneron and Vertex, according to research and consulting firm GlobalData.

More... »

Safe-Biopharma launches cyber security consulting service for life science, healthcare

Friday, April 24, 2015 01:18 PM

SAFE-BioPharma Association has created SBP Digital Trust Consulting, a resource of internationally recognized identity and access management (IAM) policy and technical experts for life science and healthcare companies seeking to develop improved cyber security strategies.

More... »

Accenture, Oracle expand Life Sciences Cloud for R&D

Friday, April 24, 2015 01:14 PM

Accenture, a global management consulting, technology services and outsourcing company, has expanded the Accenture Life Sciences Cloud for R&D, powered by Oracle, with the addition of enhanced clinical data management capabilities. This enables life sciences companies to generate high-quality, reliable and statistically sound data from clinical trials to reduce the time, effort and cost needed to take drugs from development to market.

More... »

NewLink Genetics, Merck receives Vaccine Industry Excellence Awards

Friday, April 17, 2015 01:09 PM

NewLink Genetics, a biopharmaceutical company focused on bringing novel immunotherapeutic medicines to cancer patients globally, and Merck received two Vaccine Industry Excellence (ViE) awards presented during the 15th Annual World Vaccine Congress. The ViE Awards honor the efforts, accomplishments and positive contributions of companies and individuals in the vaccine industry.

More... »

Merck chairman, CEO Kenneth C. Frazier becomes PhRMA board chairman

Friday, April 17, 2015 12:40 PM

Kenneth C. Frazier, chairman and CEO of Merck, was elected chairman of the board of the Wash. D.C.-based Pharmaceutical Research and Manufacturers of America (PhRMA). At the board meeting, PhRMA’s president and CEO John J. Castellani announced he will be retiring Jan. 1, 2016. 

More... »

Incyte joins Safe-Biopharma Association

Friday, April 17, 2015 12:39 PM

Incyte, a Delaware-based biopharmaceutical company, has joined SAFE-BioPharma Association, a nonprofit industry coalition responsible for the ongoing development and implementation of the SAFE-BioPharma digital identity and signature standard.

More... »

Arvinas, Merck to collaborate

Wednesday, April 8, 2015 12:41 PM

Arvinas, a New Haven, Conn.-based private biotechnology company creating a new class of drugs based on protein degradation, has formed a strategic collaboration with Merck in which Arvinas' novel PROTAC technology will be used to degrade target proteins to create novel therapeutics. The multi-year collaboration will encompass multiple disease targets across several therapeutic areas.

More... »


CWWeekly

May 26

inVentiv Health aims to help sponsors prepare for new E.U. regulations on observational studies

ACRP partners with CRO Analytics to measure investigative sites' views of clinical trial quality

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

May

Job satisfaction mixed as workload increases
Salaries not keeping pace with rise in work, responsibilities

Gamification moving from early science to patient use
Pharma looking to use games for early diagnosis, recruitment, adherence

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs